组织蛋白酶在糖尿病及糖尿病肾病作用机制中的研究进展

doi:10.3969/j.issn.1006-7795.2023.03.009

摘要/Abstract

摘要： 组织蛋白酶（cathepsin,CTS）是哺乳动物体内最重要的蛋白水解酶之一，在细胞内外均存在。其在体内参与多种生理、病理过程，如调节自噬、细胞凋亡、维持细胞外基质稳态、抗原提呈、病毒感染及炎症等。近年来其与代谢性疾病的关系受到了广泛关注，组织蛋白酶B（cathepsin B, CTSB）、组织蛋白酶D（cathepsin D, CTSD）、组织蛋白酶L（cathepsin L, CTSL）、组织蛋白酶S（cathepsin S, CTSS）被认为是代谢性疾病中的主要参与者，它们参与糖尿病（diabetes mellitus, DM）及糖尿病肾病（diabetic nephropathy, DN）的发病及进展过程，可能成为潜在的预测及治疗新靶点。本文主要对CTSB、CTSD、CTSL、CTSS在DM及DN中的作用及机制进行综述。

关键词: 组织蛋白酶, 糖尿病, 糖尿病肾病, 研究进展

Abstract: Cathepsin is one of the most important proteolytic enzymes in mammals, which exists both intracellularly and extracellularly. It participates in various physiological and pathological processes in vivo such as regulating autophagy, cell apoptosis, maintaining extracellular matrix homeostasis, antigen presentation, viral infection and inflammation. In recent years, cathepsin B (CTSB), cathepsin D (CTSD), cathepsin L (CTSL), and cathepsin S (CTSS) have been considered to be the main players in metabolic diseases. They are involved in the pathogenesis and progression of mellitus (DM） and diabetic nephropathy (DN) and may become potential new targets for prediction and treatment. This article reviews the role and mechanism of CTSB, CTSD, CTSL, and CTSS in DM and DN.

Key words: cathepsin, diabetes mellitus, diabetic nephropathy, research progress

中图分类号:

李明嘉, 赵苗妙, 杨金奎. 组织蛋白酶在糖尿病及糖尿病肾病作用机制中的研究进展[J]. 首都医科大学学报, 2023, 44(3): 413-419.

Li Mingjia, Zhao Miaomiao , Yang Jinkui . Research progress of cathepsin in the mechanism of diabetes and diabetic nephropathy[J]. Journal of Capital Medical University, 2023, 44(3): 413-419.

参考文献

［1］Saeedi P, Petersohn I, Salpea P, et al. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: results from the International Diabetes Federation Diabetes Atlas, 9th edition［J］. Diabetes Res Clin Pract, 2019, 157: 107843.
［2］Wang L M, Peng W, Zhao Z P, et al. Prevalence and treatment of diabetes in China, 2013－2018［J］. JAMA, 2021, 326(24): 2498－2506.
［3］Wang L M, Gao P, Zhang M, et al. Prevalence and ethnic pattern of diabetes and prediabetes in China in 2013［J］. JAMA, 2017, 317(24): 2515－2523.
［4］GBD Chronic Kidney Disease Collaboration. Global, regional, and national burden of chronic kidney disease, 1990－2017: a systematic analysis for the Global Burden of Disease Study 2017［J］. Lancet, 2020, 395(10225): 709－733.
［5］Hsing L C, Kirk E A, McMillen T S, et al. Roles for cathepsins S, L, and B in insulitis and diabetes in the NOD mouse［J］. J Autoimmun, 2010, 34(2): 96－104.
［6］Garsen M, Rops A L W M M, Dijkman H, et al. Cathepsin L is crucial for the development of early experimental diabetic nephropathy［J］. Kidney Int, 2016, 90(5): 1012－1022.
［7］Limonte C P, Valo E, Drel V, et al. Urinary proteomics identifies cathepsin D as a biomarker of rapid eGFR decline in type 1 diabetes［J］. Diabetes Care, 2022, 45(6): 1416－1427.
［8］Zhao M M, Yang W L, Yang F Y, et al. Cathepsin L plays a key role in SARS-CoV-2 infection in humans and humanized mice and is a promising target for new drug development［J］. Signal Transduct Target Ther, 2021, 6(1): 134.
［9］Yang W L, Li Q, Sun J, et al. Potential drug discovery for COVID-19 treatment targeting cathepsin L using a deep learning-based strategy［J］. Comput Struct Biotechnol J, 2022, 20: 2442－2454.
［10］Reiser J, Adair B, Reinheckel T. Specialized roles for cysteine cathepsins in health and disease［J］. J Clin Invest, 2010, 120(10): 3421－3431.
［11］Patel S, Homaei A, El-Seedi H R, et al. Cathepsins: proteases that are vital for survival but can also be fatal［J］. Biomed Pharmacother, 2018, 105: 526－532.
［12］Timur Z K, Akyildiz Demir S, Seyrantepe V. Lysosomal cathepsin a plays a significant role in the processing of endogenous bioactive peptides［J］. Front Mol Biosci, 2016, 3: 68.
［13］Joyce J A, Baruch A, Chehade K, et al. Cathepsin cysteine proteases are effectors of invasive growth and angiogenesis during multistage tumorigenesis［J］. Cancer Cell, 2004, 5(5): 443－453.
［14］Sudhan D R, Siemann D W. Cathepsin L targeting in cancer treatment［J］. Pharmacol Ther, 2015, 155: 105－116.
［15］Nishimura F, Naruishi H, Naruishi K, et al. Cathepsin-L, a key molecule in the pathogenesis of drug-induced and Ⅰ-cell disease-mediated gingival overgrowth: a study with cathepsin-L-deficient mice［J］. Am J Pathol, 2002, 161(6): 2047－2052.
［16］Puente X S, Sánchez L M, Overall C M, et al. Human and mouse proteases: a comparative genomic approach［J］. Nat Rev Genet, 2003, 4(7): 544－558.
［17］Du J, Liu Y, Fu J T. Autophagy and heart failure［J］. Adv Exp Med Biol, 2020, 1207: 223－227.
［18］Huang X D, Vaag A, Carlsson E, et al. Impaired cathepsin L gene expression in skeletal muscle is associated with type 2 diabetes［J］. Diabetes, 2003, 52(9): 2411－2418.
［19］Chen L L, Lu B, Yang Y H, et al. Elevated circulating cathepsin S levels are associated with metabolic syndrome in overweight and obese individuals［J］. Diabetes Metab Res Rev, 2019, 35(3): e3117.
［20］Ding L L, Houben T, Oligschlaeger Y, et al. Plasma cathepsin D activity rather than levels correlates with metabolic parameters of type 2 diabetes in male individuals［J］. Front Endocrinol (Lausanne), 2020, 11: 575070.
［21］Ding L L, Goossens G H, Oligschlaeger Y, et al. Plasma cathepsin D activity is negatively associated with hepatic insulin sensitivity in overweight and obese humans［J］. Diabetologia, 2020, 63(2): 374－384.
［22］Jobs E, Risérus U, Ingelsson E, et al. Serum cathepsin S is associated with decreased insulin sensitivity and the development of type 2 diabetes in a community-based cohort of elderly men［J］. Diabetes Care, 2013, 36(1): 163－165.
［23］Beijer K, Nowak C, Sundstrm J, et al. In search of causal pathways in diabetes: a study using proteomics and genotyping data from a cross-sectional study［J］. Diabetologia, 2019, 62(11): 1998－2006.
［24］Suh M J, Tovchigrechko A, Thovarai V, et al. Quantitative differences in the urinary proteome of siblings discordant for type 1 diabetes include lysosomal enzymes［J］. J Proteome Res, 2015, 14(8): 3123－3135.
［25］Maehr R, Mintern J D, Herman A E, et al. Cathepsin L is essential for onset of autoimmune diabetes in NOD mice［J］. J Clin Invest, 2005, 115(10): 2934－2943.
［26］Wicker L S, Todd J A, Peterson L B. Genetic control of autoimmune diabetes in the NOD mouse［J］. Annu Rev Immunol, 1995, 13: 179－200.
［27］Reed B, Crawford F, Hill R C, et al. Lysosomal cathepsin creates chimeric epitopes for diabetogenic CD4 T cells via transpeptidation［J］. J Exp Med, 2021, 218(2): e20192135.
［28］Kryvalap Y, Jiang M L, Kryvalap N, et al. SerpinB13 antibodies promote β cell development and resistance to type 1 diabetes［J］. Sci Transl Med, 2021, 13(588): eabf1587.
［29］Crawford S A, Wiles T A, Wenzlau J M, et al. Cathepsin D drives the formation of hybrid insulin peptides relevant to the pathogenesis of type 1 diabetes［J］. Diabetes, 2022, 71(12): 2793－2803.
［30］Woods C C, Sundar K, Tessler C, et al. Tissue inhibitor of metalloproteinase-2 inhibits T-cell infiltration and preserves pancreatic beta-cell function in an in vitro type 1 diabetes mellitus model［J］. J Autoimmun, 2006, 27(1): 28－37.
［31］Yang M, Zhang Y O, Pan J H, et al. Cathepsin L activity controls adipogenesis and glucose tolerance［J］. Nat Cell Biol, 2007, 9(8): 970－977.
［32］Urbich C, Dernbach E, Rssig L, et al. High glucose reduces cathepsin L activity and impairs invasion of circulating progenitor cells［J］. J Mol Cell Cardiol, 2008, 45(3): 429－436.
［33］Lafarge J C, Pini M, Pelloux V, et al. Cathepsin S inhibition lowers blood glucose levels in mice［J］. Diabetologia, 2014, 57(8): 1674－1683.
［34］Karimkhanloo H, Keenan S N, Sun E W, et al. Circulating cathepsin S improves glycaemic control in mice［J］. J Endocrinol, 2021, 248(2): 167－179.
［35］Guicciardi M E, Deussing J, Miyoshi H, et al. Cathepsin B contributes to TNF-α-mediated hepatocyte apoptosis by promoting mitochondrial release of cytochrome c［J］. J Clin Invest, 2000, 106(9): 1127－1137.
［36］Assady S, Benzing T, Kretzler M, et al. Glomerular podocytes in kidney health and disease［J］. Lancet, 2019, 393(10174): 856－858.
［37］Lin J S, Susztak K. Podocytes: the weakest link in diabetic kidney disease?［J］. Curr Diab Rep, 2016, 16(5): 45.
［38］Faul C, Donnelly M, Merscher-Gomez S, et al. The actin cytoskeleton of kidney podocytes is a direct target of the antiproteinuric effect of cyclosporine A［J］. Nat Med, 2008, 14(9): 931－938.
［39］Sever S, Altintas M M, Nankoe S R, et al. Proteolytic processing of dynamin by cytoplasmic cathepsin L is a mechanism for proteinuric kidney disease［J］. J Clin Invest, 2007, 117(8): 2095－2104.
［40］Hinden L, Kogot-Levin A, Tam J, et al. Pathogenesis of diabesity-induced kidney disease: role of kidney nutrient sensing［J］. FEBS J, 2022, 289(4): 901－921.
［41］Yokota S, Tsuji H, Kato K. Immunocytochemical localization of cathepsin B in rat kidney.Ⅰ. Light microscopic study using the indirect immunoenzyme technique［J］. J Histochem Cytochem, 1986, 34(7): 891－897.
［42］Saudenova M, Promnitz J, Ohrenschall G, et al. Behind every smile theres teeth: cathepsin Bs function in health and disease with a kidney view［J］. Biochim Biophys Acta Mol Cell Res, 2022, 1869(4): 119190.
［43］Medina-Navarro R, Torres-Ramos Y D, Guzmán-Grenfell A M, et al. Lysosomal dysfunction induced by changes in albumins tertiary structure: potential key factor in protein toxicity during diabetic nephropathy［J］. Life Sci, 2019, 230: 197－207.
［44］Markmann S, Thelen M, Cornils K, et al. Lrp1/LDL receptor play critical roles in mannose 6-phosphate-independent lysosomal enzyme targeting［J］. Traffic, 2015, 16(7): 743－759.
［45］Mason R M, Wahab N A. Extracellular matrix metabolism in diabetic nephropathy［J］. J Am Soc Nephrol, 2003, 14(5): 1358－1373.
［46］Cocchiaro P, De Pasquale V, Della Morte R, et al. The multifaceted role of the lysosomal protease cathepsins in kidney disease［J］. Front Cell Dev Biol, 2017, 5: 114.
［47］Kumar Vr S, Darisipudi M N, Steiger S, et al. Cathepsin S cleavage of protease-activated receptor-2 on endothelial cells promotes microvascular diabetes complications［J］. J Am Soc Nephrol, 2016, 27(6): 1635－1649.
［48］Goldberg R, Rubinstein A M, Gil N, et al. Role of heparanase-driven inflammatory cascade in pathogenesis of diabetic nephropathy［J］. Diabetes, 2014, 63(12): 4302－4313.
［49］Grimm S, Horlacher M, Catalgol B, et al. Cathepsins D and L reduce the toxicity of advanced glycation end products［J］. Free Radic Biol Med, 2012, 52(6): 1011－1023.
［50］Li Y Y, Fang J, Ao G Z. Cathepsin B and L inhibitors: a patent review (2010-present)［J］. Expert Opin Ther Pat, 2017, 27(6): 643－656.
［51］Hilpert H, Mauser H, Humm R, et al. Identification of potent and selective cathepsin S inhibitors containing different central cyclic scaffolds［J］. J Med Chem, 2013, 56(23): 9789－9801.
［52］Hargreaves P, Daoudlarian D, Theron M, et al. Differential effects of specific cathepsin S inhibition in biocompartments from patients with primary Sjgren syndrome［J］. Arthritis Res Ther, 2019, 21(1): 175.
［53］Kumar Vr S, Darisipudi M N, Steiger S, et al. Cathepsin S cleavage of protease-activated receptor-2 on endothelial cells promotes microvascular diabetes complications［J］. J Am Soc Nephrol, 2016, 27(6): 1635－1649.
［54］Kwok H F, Buick R J, Kuehn D, et al. Antibody targeting of cathepsin S induces antibody-dependent cellular cytotoxicity［J］. Mol Cancer, 2011, 10(1): 147.
［55］Liaudet-Coopman E, Beaujouin M, Derocq D, et al. Cathepsin D: newly discovered functions of a long-standing aspartic protease in cancer and apoptosis［J］. Cancer Lett, 2006, 237(2): 167－179.
［56］Liang Z G, Liu Z L, Sun X W, et al. The effect of fucoidan on cellular oxidative stress and the CatD-Bax signaling axis in MN9D cells damaged by 1-methyl-4-phenypyridinium［J］. Front Aging Neurosci, 2019, 10: 429.
［57］Singh M P, Sharma C, Kang S C. Morin hydrate attenuates adenine-induced renal fibrosis via targeting cathepsin D signaling［J］. Int Immunopharmacol, 2021, 90: 107234.
［58］Houtecká R, Hadzima M, Fanfrlík J, et al. Biomimetic macrocyclic inhibitors of human cathepsin D: structure-activity relationship and binding mode analysis［J］. J Med Chem, 2020, 63(4): 1576－1596.
［59］Matarrese P, Ascione B, Ciarlo L, et al. Cathepsin B inhibition interferes with metastatic potential of human melanoma: an in vitro and in vivo study［J］. Mol Cancer, 2010, 9: 207.
［60］Balaji K N, Schaschke N, Machleidt W, et al. Surface cathepsin B protects cytotoxic lymphocytes from self-destruction after degranulation［J］. J Exp Med, 2002, 196(4): 493－503.

[1]	李雨阳, 朱晓蓉, 刘婧, 郑晓敏, 杨金奎, 杨芳远. 糖尿病肾病患者触珠蛋白基因多态性及血清触珠蛋白浓度分析[J]. 首都医科大学学报, 2023, 44(3): 375-380.
[2]	夏宁, 聂秀红, 王美平, 冯志红, 穆志静, 樊晓君. 阻塞性睡眠呼吸暂停与单纯鼾症患者的睡眠效率与糖尿病患病率的相关性研究[J]. 首都医科大学学报, 2023, 44(3): 487-496.